Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors
, , , , , , , , , , y
27 feb 2025
Acerca de este artículo
Categoría del artículo: research article
Publicado en línea: 27 feb 2025
Páginas: 100 - 109
Recibido: 23 ene 2025
Aceptado: 04 feb 2025
DOI: https://doi.org/10.2478/raon-2025-0017
Palabras clave
© 2025 Tim Wilke et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
FIGURE 2.
Response to percutaneous electrochemotherapy (pECT) treatment in the 2 groups
| RESPONSE | i.v. pECT (N = 21) | i.a. pECT (N = 31) | P value | P value | ||
|---|---|---|---|---|---|---|
| N | % | N | % | Overall distribution | CR |
|
| 13 | 61.9% | 25 | 80.6% | 0.3454 | 0.1349 | |
| 5 | 23.8% | 4 | 12.9% | |||
| 1 | 4.8% | 0 | 0.0% | |||
| 0 | 0.0% | 1 | 3.2% | |||
| 2 | 9.5% | 1 | 3.2% | |||
Descriptive characteristics of the patients in the 2 groups
| PATIENTS | i.v. pECT (N = 18) | i.a. pECT (n = 26) | P value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| |
8 | 44% | 15 | 58% | 0.5406 |
| |
10 | 56% | 11 | 42% | |
| |
7 | 39% | 10 | 38% | 0.4620 |
| |
4 | 22% | 4 | 15% | |
| |
2 | 11% | 2 | 8% | |
| |
0 | 0% | 3 | 12% | |
| |
2 | 11% | 0 | 0% | |
| |
1 | 6% | 2 | 8% | |
| |
1 | 6% | 0 | 0% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
0 | 0% | 1 | 4% | |
| |
1 | 6% | 0 | 0% | |
| Synchronous | 8 | 44% | 16 | 62% | 0.5343 |
| Metachronous | 8 | 44% | 8 | 31% | |
| No | 2 | 11% | 2 | 7% | |
| None | 9 | 50% | 17 | 65% | 0.3613 |
| Yes | 9 | 50% | 9 | 35% | |
| Lung | 3 | 17% | 3 | 12% | 0.6025 |
| Bone | 1 | 6% | 2 | 8% | |
| Kidney | 1 | 6% | 1 | 4% | |
| Lung + bone + brain | 1 | 6% | 0 | 0% | |
| Bone + peritoneum | 1 | 6% | 0 | 0% | |
| Pleural + bone | 1 | 6% | 0 | 0% | |
| Retroperineal | 1 | 6% | 0 | 0% | |
| Adrenal gland | 0 | 0% | 1 | 4% | |
| Lymphnode | 0 | 0% | 1 | 4% | |
| Bone + lymphnode | 0 | 0% | 1 | 4% | |
| Systemic therapy | 16 | 89% | 26 | 100% | 0.1617 |
| Liver surgery | 4 | 22% | 12 | 46% | 0.1251 |
| Local treatments | 11 | 61% | 8 | 31% | 0.0657 |
| TACE | 8 | 43% | 4 | 15% | 0.1529 |
| TACE+RFA | 1 | 6% | 0 | 0% | |
| TACE+CP | 1 | 6% | 0 | 0% | |
| TACE/MWA/CRYOTH | 0 | 0% | 2 | 8% | |
| CRYOTH | 1 | 6% | 0 | 0% | |
| IBT | 0 | 0% | 2 | 8% | |
| Cardiac diseases | 6 | 33% | 7 | 27% | 0.7422 |
| Pulmonary diseases | 3 | 17% | 7 | 27% | 0.4889 |
| Liver diseases | 9 | 50% | 0 | 0% | <0.0001 |
| 1 | 15 | 83% | 21 | 81% | 1.000 |
| 2 | 3 | 17% | 5 | 19% | |
Characteristics of target lesions in the 2 groups
| LESIONS | i.v. pECT (N = 21) | i.a. pEC (N = 31) | P value | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Hypervascular | 2 | 9.5% | 5 | 16.1% | 0.7664 |
| Intermediate | 14 | 66.7% | 20 | 64.5% | |
| Hypovascular | 5 | 23.8% | 6 | 19.4% | |
| Yes | 19 | 90.5% | 21 | 67.7% | 0.0927 |
| No | 2 | 9.5% | 10 | 32.3% | |
| Distant (> 10 mm) | 4 | 19.0% | 8 | 25.8% | 0.5389 |
| Close (1 mm to 10 mm) | 6 | 28.6% | 5 | 16.1% | |
| Adjacent (< 1 mm) | 11 | 52.4% | 18 | 58.1% | |
| Yes | 7 | 33.3% | 8 | 25.8% | 0.7559 |
| No | 14 | 66.7% | 23 | 74.2% | |
| TACE (transarterial chemoembolization) | 6 | 28.6% | 4 | 12.9% | 0.1474 |
| CP (chemoperfusion) | 1 | 4.8% | 0 | 0.0% | |
| IBT (interstitial brachytherapy) | 0 | 0.0% | 2 | 6.5% | |
| TACE/MWA/CRYOTH | 0 | 0.0% | 2 | 6.5% | |
| Yes | 20 | 95.2% | 31 | 100.0% | 0.2199 |
| No | 1 | 4.8% | 0 | 0.0% | |